Phase 3 trials of oral tavapadon in easing motor symptoms nearing end

An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist aiming to improve motor function in people with Parkinson’s disease, expects to release study findings next year. Three separate, 27-week trials are evaluating tavapadon’s efficacy, safety, and tolerability against…

First Patients Dosed in Phase 3 Trials Testing Tavapadon in Parkinson’s Patients

The first patients have been dosed in three Phase 3 clinical trials evaluating the safety and effectiveness of tavapadon, Cerevel Therapeutics’ lead investigational oral therapy, in people with Parkinson’s disease. The studies, which were paused temporarily due to the COVID-19 pandemic, will test tavapadon as a…